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ABSTRACT 
Background: Several serological assays have been developed to detect anti-SARS-CoV-2 IgG 
antibodies, but evidence about their comparative performance is limited. We sought to assess 
the sensitivity of four anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assays (ELISA) in 
individuals with evidence of prior SARS-CoV-2 infection.  
 
Methods: We obtained sera from 36 individuals with PCR-confirmed SARS-CoV-2 infection 
between March and May 2020. We evaluated samples collected at around 21 days (±14 days) 
after their initial PCR test using 3 commercially available ELISA assays, two anti-spike (Ortho-
Clinical Diagnostics Vitros, and Euroimmun) and one anti-nucleocapsid (Abbott Architect), and a 
Yale-developed anti-spike ELISA test. We determined the sensitivity of the tests and compared 
their results. The Euroimmun and Yale ELISA had an equivocal and indeterminate category, 
which were considered as both negative and positive. 
 
Results: Among the 36 individuals with SARS-CoV-2 infection, mean age was 43 (±13) years 
and 19 (53%) were female. The sensitivities of the tests were not significantly different (Abbott 
Architect, Ortho Vitros, Euroimmmun, and Yale assays: 86% (95% confidence interval [CI], 71–
95), 94% (95% CI, 81–99), 86% (95% CI, 71–95), and 94% (95% CI, 81–99), respectively; p-
value=0.464). The sensitivities of the Euroimmun and Yale ELISA tests increased when the 
equivocal/indeterminate results were considered positive (97% [95% CI, 85–100] and 100% 
[95% CI, 90–100], respectively), but were not significantly different from other tests (p=0.082). 
The cross-correlation coefficient ranged from 0.85–0.98 between three anti-spike protein assays 
(Ortho Vitros, Euroimmun, Yale) and was 0.58–0.71 between the three anti-spike protein assays 
and the anti-nucleocapsid assay (Abbott).  
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Conclusion: The sensitivities of four anti-SARS-CoV-2 protein assays did not significantly 
differ, although the sample size was small. Sensitivity also depended on the interpretation of 
equivocal and indeterminate results. The strongest correlations were present for the three anti-
spike proteins assays. These findings suggest that individual test characteristics and the 
correlation between different tests should be considered when comparing or aggregating data 
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BACKGROUND 
Serological testing is being increasingly used to evaluate people for antibodies to severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recently, a number of serology tests 
have been developed and have received Food and Drug Administration (FDA) Emergency Use 
Authorization (EUA) for the detection of these antibodies.1 However, there are relatively few 
evaluations of these tests from a cross-section of individuals with polymerase chain reaction test 
confirmed SARS-CoV-2 infection.  
Accordingly, we sought to determine the sensitivity of three commercially available 
SARS-CoV-2 IgG assays and an anti-spike enzyme-linked immunosorbent assay (ELISA) test 
at Yale University, in preparation for conducting a large seroprevalence survey of a 
representative population sample for the state of Connecticut, USA. We compared the Abbott 
Architect, the Ortho Vitros and Euroimmun, all of which are approved by the US FDA. The 
Abbott Architect SARS-CoV-2 IgG assay detects antibodies against the nucleocapsid, whereas 
the Ortho Vitros anti-SARS-CoV-2 IgG test and Euroimmun SARS-CoV-2 ELISA detect 
antibodies against the spike protein of the virus.2 We also compared the results of these 
antibody tests with each other.  
 
MATERIAL AND METHODS 
Patient Sample 
We took advantage of previously collected and de-identified serum specimens from 36 
individuals with confirmed SARS-CoV-2 infection between March and May 2020 and the 
availability of resources to test them with the commercially available assays, which set the 
sample size. Patients were defined as SARS-CoV-2 positive based on reverse transcription 
polymerase chain reaction (RT-PCR) testing on nasopharyngeal swab specimens collected. 
The serology samples included individuals with variable severity and duration of symptoms, but 
all samples were collected when individuals were asymptomatic and in convalescence, 
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approximately 21 days (±14 days) after their initial RT-PCR test. For non-hospitalized 
individuals, answers to questions from survey data and telephone interviews were used to 
identify individuals who self-reported symptoms that they attributed to COVID-19 infection. All 
individuals provided informed consent and samples were collected in accordance with protocols 
approved by the Institutional Review Board at Yale University. 
 
Sampling Methodology and IgG Testing 
Blood was collected in vacutainer tubes, and serum was separated. Serum aliquots were 
stored at -80°C. Samples had previously been assayed on a laboratory developed test at Yale, 
an ELISA against the spike antigen, but samples were selected blinded from these results. A 
cutoff of 0.32 was used for the Yale anti-spike ELISA to identify positive samples, with 0.28-0.32 
considered indeterminate. Approximately 450uL of serum from each of the 36 samples was sent 
from Yale to Quest Diagnostics for testing on their 3 commercially-available SARS-CoV-2 IgG 
assays, namely – Abbott Architect SARS-CoV-2 IgG test, Ortho-Clinical Diagnostics Vitros anti-
SARS-CoV-2 IgG test, and Euroimmun SARS-CoV-2 ELISA (IgG).2 Testing was performed in a 
blinded manner.  
Antibody levels were expressed as the ratio of chemiluminescence values over the cutoff 
(S/CO) values. The following cutoffs were used for reporting of results according to the 
manufacturer’s instructions: 1) Abbott Architect IgG assay3: <1.4 = negative and ≥1.4 = positive; 
2) Ortho Vitros IgG assay4: <1.00 = negative and ≥1.00 = positive; and 3) Euroimmun IgG 
assay5: <0.8 = negative, ≥0.8 to <1.1 = equivocal, and ≥1.1 = positive.  
 
Data Analysis and Visualization 
We collected data on the optical density of the Yale anti-spike ELISA and the index 
values for Abbott Architect, Ortho Vitros, and Euroimmun SARS-CoV-2 IgG assays, and 
compared the results reported by the four serology assays. The sensitivity of different assays 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 30, 2020. .https://doi.org/10.1101/2020.07.29.20164343doi: medRxiv preprint 
 6
was calculated, and Fishers exact test was used to detect for statistical difference. The 
correlation between the index values of different assays and optical density of Yale anti-spike 
ELISA was assessed using Spearman’s correlation coefficient, with confidence intervals (CI) 
calculated by z-transformation. Individual scatter plots were created for each two-way test 
comparison with non-parametric locally weighted regression (Loess) smoothing with 95% CI. 
SAS and R (version 3.6.1) was used for all statistical analyses and graphical and tabular 




Of the 36 individuals with SARS-CoV-2 infection included in the study, mean age 43 
(±13) years and 19 were female, 16 were male, and 1 did not have information available on 
gender. 
 
Sensitivity of the SARS-CoV-2 IgG Assays 
Sensitivity of the Abbott Architect, Ortho Vitros, Euroimmun, and Yale ELISA SARS-
CoV-2 IgG assays is shown in Table 1, based on the results in 36 individuals with RT-PCR 
confirmed SARS-CoV-2 infection.  
The Abbott Architect IgG assay identified 31 samples as true positives and 5 samples as 
false negatives, and had a sensitivity of 86% (95% CI, 71% to 95%). The Othro Vitros IgG assay 
identified 34 samples as true positives and 2 samples as false negatives, yielding a sensitivity of 
94% (95% CI, 81% to 99%). Euroimmun IgG assay identified 31 samples as true positives, 1 
sample as false negative, and 4 as equivocal. The sensitivity of the assay considering equivocal 
samples as positives was 97% (95% CI, 85% to 100%), whereas the sensitivity was 86% (95% 
CI, 71% to 95%) when the equivocal samples were considered as negatives. The Yale anti-
spike ELISA identified 34 samples as true positives and 2 as indeterminate. The sensitivity of 
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the assay considering the indeterminate as positives was 100% (95% CI, 90% to 100%), 
whereas the sensitivity was 94% (95% CI, 91% to 99%) when the indeterminate samples were 
considered as negatives. Overall, sensitivities of the four anti-SARS-CoV-2 protein assays did 
not differ significantly whether indeterminate/equivocal samples were considered as positives 
(p=0.082) or as negatives (p=0.464). 
 
Correlation Between Different Assays 
The 36 serum samples from individuals with RT-PCR-confirmed SARS-CoV-2 infection 
showed varied index values on Abbott (range 0.02–8.81), Ortho Vitros (range 0.01–20.70), and 
Euroimmun (range 0.13–8.60) IgG assays. The optical density of IgG on the Yale anti-spike 
ELISA ranged from 0.30 to 3.07. 
The index values of Abbott Architect, Ortho Vitros, and Euroimmun SARS-CoV-2 IgG 
assays had a correlation of 0.58 (95% CI, 0.32 to 0.77), 0.85 (95% CI, 0.72 to 0.92), and 0.85 
(95% CI, 0.72 to 0.92), respectively, compared with the optical density of Yale anti-spike ELISA 
(Figure 1 A, B, C). The correlations between the index values of the 3 different commercial 
SARS-CoV-2 IgG assays are shown in Figure 1 (D, E, F). The Ortho Vitros and Abbott Architect 
SARS-CoV-2 IgG assays had a correlation of 0.71 (95% CI, 0.50 to 0.84), Euroimmun and 
Abbott Architect IgG assays had a correlation of 0.66 (95% CI, 0.42 to 0.81), and Euroimmun 
and Ortho Vitros IgG assays had a correlation of 0.98 (95% CI, 0.96 to 0.99). Compared with 
each other and with the Yale anti-spike ELISA, the Euroimmun and Ortho Vitros IgG assays had 
the highest correlation, and Abbott Architect assay had the lowest correlations when compared 
with the other two assays, as well as to the Yale anti-spike ELISA.   
 
DISCUSSION 
This study assessed the performance characteristics of four anti-SARS-CoV-2 serology 
tests in individuals with a prior SARS-CoV-2 infection. The sensitivities of the tests were not 
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significantly different, and the quantitative scales of all assays were strongly correlated with 
Spearman coefficients greater than 0.58 and p<0.001 in all cases. While the Ortho Vitros and 
the Euroimmun assays had a very strong correlation with each other, and good correlation with 
the Yale anti-spike ELISA, the Abbott Architect assay, the only anti-nucleocapsid test, exhibited 
lower correlation with the three other tests in the comparison. 
The 3 different FDA EUA SARS-CoV-2 IgG assays and the Yale anti-spike ELISA used 
in this study detect antibodies directed against different immunogenic components of SARS-
CoV-2. The spike protein is the main surface glycoprotein of SARS-CoV-2 that is used to attach 
and enter cells,6 whereas the nucleocapsid is critical for viral transcription and replication. Initial 
studies suggested that assays using the SARS-CoV-2 nucleoprotein may have higher 
sensitivity.7,8 However, the data presented here show a qualitatively higher sensitivity with the 3 
assays that use the spike glycoprotein (Ortho Vitros, Euroimmun, Yale ELISA), as compared 
with the Abbott Architect assay, suggesting a need for further comparative testing. Additionally, 
as expected, the 3 anti-spike assays had a stronger correlation among themselves as compared 
with the anti-nucleocapsid assay. 
Given that the sensitivities of four anti-SARS-CoV-2 protein assays did not significantly 
differ, it may be reasonable to use any of these assays to assess the prevalence of SARS-CoV-
2 antibodies. However, recognizing differences in the correlation between these assays can 
help facilitate interpretation of prevalence studies using the different assays. For example, given 
the very strong correlation between Euroimmun and Ortho Vitros assays, it would be reasonable 
to aggregate seroprevalence studies that use these assays into meta-analysis of 
seroprevalence or a comparison over time. The weaker correlation of the Abbott Architect with 
the other serology assays, however, suggest caution should be used when aggregating 
seroprevalence rates detected by the Abbott Architect assay with those using other serologic 
assays. Studies focusing on assessment of seroprevalence of COVID-19 in the different 
populations should consider for the sensitivity of the assay used, and the likely prevalence of 
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antibodies in the population, in order to accurately interpret the results. It is also important to 
know the thresholds for positivity and how tests in the indeterminate range are reported.  
Our study has several limitations. Our comparative study focused on the distribution and 
correlation of anti-SARS-CoV-2 IgG ELISA results among individuals who had confirmed 
COVID-19, and we were not able to evaluate the specificities of the tests. In addition, our 
sample size limited our power to detect clinically meaningful differences in sensitivities. Another 
limitation is that we had limited information on the clinical characteristics of these individuals, 
which could have affected the nature of antibody response. Nevertheless, this study provides 
important information on the correlations between 3 commercially available serology tests, as 
well as the Yale anti-spike ELISA, and also information on the sensitivity of these tests, which 
can help guide future research on the seroprevalence of IgG antibodies to SARS-CoV-2. 
In conclusion, this study shows that the 3 commercial SARS-CoV-2 IgG assays (Abbott 
Architect, Ortho Vitros, and Euroimmun) and the Yale anti-spike ELISA, had sensitivities that 
were not significantly different. Additionally, the 3 assays based on the spike protein showed the 
strongest correlations in detecting SARS-CoV-2 antibodies and had a weaker correlation with 
the serology test based on the nucleocapsid protein. As such, serologic surveillance of past 
SARS-CoV-2 infection should consider the individual test characteristics and the correlation 
between different tests when comparing or aggregating data across different populations. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 30, 2020. .https://doi.org/10.1101/2020.07.29.20164343doi: medRxiv preprint 
 10
DISCLOSURES: Dr. Krumholz works under contract with the Centers for Medicare & Medicaid 
Services to support quality measurement programs; was a recipient of a research grant, through 
Yale, from Medtronic and the United States Food and Drug Administration to develop methods 
for post-market surveillance of medical devices; was a recipient of a research grant with 
Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale 
University, to support clinical trial data sharing; was a recipient of a research agreement, 
through Yale University, from the Shenzhen Center for Health Information for work to advance 
intelligent disease prevention and health promotion; collaborates with the National Center for 
Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for 
work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work 
related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for 
work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was 
a participant/participant representative of the IBM Watson Health Life Sciences Board; is a 
member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the 
Physician Advisory Board for Aetna; and is a co-founder of HugoHealth, a personal health 
information platform, and co-founder of Refactor Health, an enterprise healthcare artificial 





 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 30, 2020. .https://doi.org/10.1101/2020.07.29.20164343doi: medRxiv preprint 
 11
REFERENCES 
1. EUA Authorized Serology Test Performance. U.S. Food & Drug Administration. 
https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-
authorized-serology-test-performance. Accessed July 27, 2020. 
2. Bryan A, Pepper G, Wener MH, et al. Performance Characteristics of the Abbott 
Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. Journal of 
Clinical Microbiology. 2020:JCM.00941-00920. 
3. Abbott Architect SARS-CoV-2 IgG. Instructions To Use. EUA Authorized Serology Test 
Performance. https://www.fda.gov/media/137383/download: U.S. Food and Drug 
Administration; Accessed July 27, 2020. 
4. Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG test. Instructions To Use. 
EUA Authorized Serology Test Performance. 
https://www.fda.gov/media/136967/download: U.S. Food and Drug Administration; 
Accessed July 27, 2020. 
5. Euroimmun SARS-CoV-2 ELISA (IgG). Instructions for Use. EUA Authorized Serology 
Test Performance. https://www.fda.gov/media/137609/download: U.S. Food and Drug 
Administration; Accessed July 27, 2020. 
6. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, 
and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-
292.e286. 
7. Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in Detection of Antibodies to 
Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 
in Patients With Coronavirus Disease 2019. The Journal of Infectious Diseases. 
2020;222(2):206-213. 
8. Cheng MP, Yansouni CP, Basta NE, et al. Serodiagnostics for Severe Acute Respiratory 
Syndrome-Related Coronavirus-2: A Narrative Review. Ann Intern Med. 2020. 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 30, 2020. .https://doi.org/10.1101/2020.07.29.20164343doi: medRxiv preprint 
 12
Table 1. Sensitivity of different SARS-CoV-2 IgG Assays (n = 36 positive RT-PCR) 
SARS-CoV-2 IgG Assay True Positives, n False Negatives, n Sensitivity, % (95% CI) 
Abbott Architect 31 5 86% (71% to 95%) 
Vitros 34 2 94% (81% to 99%) 
Euroimmun 
   
Equivocal results as positive 35 1 97% (85% to 99%) 
Equivocal results as negative 31 5 86% (71% to 95%) 
Yale ELISA    
Indeterminate as positives 36 0 100% (90% to 100%) 
Indeterminate as negative 34 2 94% (81% to 99%) 
Abbreviations: CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; SARS-CoV-2, severe acute 
respiratory syndrome coronavirus 2. 
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Figure 1. Correlations between the Yale Anti-Spike ELISA, Abbott Architect, Ortho Vitros, and 
Euroimmun SARS-CoV-2 IgG Assays. The dashed line represents the cutoffs used. 
 
Abbreviations: CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; SARS-CoV-2, 
severe acute respiratory syndrome coronavirus 2. 
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